Navigation Links
An Image-Based Assay of Endothelial Cell Tube Formation as a Model of Angiogenesis


Formation of new blood vessels is fundamental to the development of cancerous cell masses and has therefore been the focus of many drug screening and cell signaling research studies. Blood vessel development is a significant event in the development and growth of solid tumors, and is implicated in wound healing, retinopathy and macular degeneration.

Traditional animal models to quantify the degree of blood vessel formation are being replaced by cell culture assays that are easier to set up, statistically reliable and can be automated in a drug screening laboratory.1,2

These assays rely on the endothelial cells ability to form distinct blood-vessel-like tubules in an extracellular matrix (BD Matrigel Matrix) where they can subsequently be visualized by fluorescence microscopy. Although quantification of the tubules can be performed by manual tracing, this method precludes the use of the assay in unbiased high-throughput applications. Much preferred is the use of an automated confocal imaging system such as the BD Pathway Bioimager with sophisticated image and data analysis algorithms. The assay is designed to work with live cells in order to avoid fixation artifacts such as the disruption of tubules.


Human Umbilical Vein Endothelial Cells (BD HUVEC-2, Cat. No. 354151) were maintained in EGM-2 (Cambrex, CC-3156). The cells were washed and trypsinized (trypsin- EDTA, Cambrex, CC-5012) then resuspended into basal media (Cambrex, CC-3162) containing 0.1% BSA (Cat. No. 354331) and seeded into BD BioCoat Angiogenesis System: Endothelial Cell Tube Formation plates (Cat. No. 354150) at 20,000 cells/well and incubated for 16 to 18h at 37C (5% CO 2 ). These plates contain an optimized BD Matrigel Matrix which promotes endothelial cell tube formation. Suramin (Calbiochem, 574625) was used to generate dose response curves from 0.3 to 160 μM. Suramin was solubilized in H2O and serially diluted into basal media containing 0.1% BSA.

After 16-18h, the media was discarded and cells were washed twice with Hanks Balanced Salt Solution (HBSS) and stained with Calcein AM (Invitrogen, C-3100MP), 8 μg/mL for 30 minutes at 37C/ 5% CO 2. The dye was discarded and cells were washed twice to remove excess dye. Some preparations were fixed with warmed 1% paraformaldehyde (in HBSS), washed twice with PBS and labeled with Alexa 488 Phalloidin (Invitrogen, A12379, 1:200 dilution).

Cells were imaged on the BD Pathway Bioimager in confocal and non-confocal mode using the 4 (NA 0.13) objective for quantification of tubule formation and 10 (NA 0.3) to generate higher resolution images.


Initial results suggested that the tube formation event occurs across several focal planes, even with the low magnification used. This is not surprising considering that the endothelial cells are known to actively migrate into the BD Matrigel Matrix. We therefore employed a new feature of the BD Pathway Bioimager to automatically generate a single image representing the in-focus portion of multiple Z sections across a plate. This collapsed stack feature was combined with the ability of the system to acquire confocal images, thus ensuring a high degree of optical sample flatness even before the image was analyzed. Image analysis was conducting using the new BD Tube Formation Module, an advanced development of the BD Neurite Outgrowth Module (Cat. No. 346203). The algorithm thresholds the cells from the background and identifies a number of features including, the total length of the tubules, the total area of the tubules and the total number of segments. The software allows both turn-key analysis using default values as well as adjustment of parameters for the development of specific assays. The software allows cellular debris or non-connected tube fragments to be removed prior to data analysis. The data generated is contained in text files and easily analyzed using BD Image Data Explorer (Cat. No. 341039).

Control images ( Figure 3 , left panel) obtained with the BD Pathway Bioimager show distinct development of tubes indicating that endothelial cells indeed do resemble blood vessels. The image in Figure 1 was acquired using a 10 objective and shows very clear development of endothelial cell-derived tubules. These tubules mostly originate at aggregates of cells and appear to actively connect with other tubules or aggregates. The total number of tubes formed ( Figure 3 and Figure 4 ) is an important measurement parameter since the underlying signaling and gene expression processes which mediates tube formation may offer an attractive leverage point for drug development.


The advent of automated imaging platforms such as the BD Pathway Bioimager allow the migration of microscopebased assays into the drug discovery and systems biology arena. For this to succeed, images not only need to be acquired in a highly reproducible and hands-off manner but must also be analyzed with minimal user intervention. We present here such an assay consisting of human endothelial cells, 96-well coated plates, an automated imaging system and data analysis software. Confocal microscopy combined with the collapsed stack feature of the BD Pathway Bioimager enables analysis of angiogenic tubules in a 3 dimensional matrix that better resembles the native physiological environment. Alternative methods using non-confocal systems are being used where the matrix is dried out overnight to collapse the cells into a flat plane this can not be done on live cells and may create significant distortions in the fragile branching structure of the sample.

Blood vessel formation is an important target in the treatment of multiple diseases including several cancer types. In the small molecule screening phase of drug discovery, animal experiments are low throughput and often technically too challenging, expensive and ambiguous to be used. Scoring the degree of blood vessel formation using an unbiased microscope approach allows this assay to be used in secondary screening applications against hundreds or thousands of putative drugs. Although cell culture experiments can currently not fully replace animal experiments, they aide in reducing the number of compounds to be tested and thus accelerate drug development and our understanding of cellular signaling events.


1. Auerbach, R., Lewis, R., Shinners, B., Kubai, L., Akhtar, N. 2003. Angiogenesis Assay: A Critcial Overview. Clinical Chemistry. 49:1, 32-40.

2. Taraboletti, G., Giavazzi, R. 2004. Modelling approaches for angiogenesis. EJC . 40, 881-889.

3. Fu, X.W, Nurse, C.A., Cutz, E. 2004. Expression of functional purinergic receptors in pulmonary neuroepithelial bodies and their role in hypoxia chemotransmission. Biochem. J. 385 (3-4), 275-284.



Page: All 1 2 3 4

Related biology technology :

1. Caspase-3 Activation - An Indicator of Apoptosis in Image-Based Assays
2. A Positive Selection Assay for Mutation Analysis in Big Blue Animals
3. Luminol-enhanced Assay for Superoxide Anion (O2 face="Symbol" )
4. Organize Your Data from the Big Blue Mutation Assay
5. Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations
6. RNase Protection Assay (RPA) Using DIG-Labeled RNA Probes
7. measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay
8. Matched siRNAs and Assays: Ambion + Applied Biosystems = RNAi Success
9. Using Validated siRNAs in Functional Genomic Assays
10. Nuclease Protection Assays: The Basics
11. RNArticles: RNA Amplification Used to Develop a New In Vitro HCMV Assay
Post Your Comments:

(Date:11/24/2015)... , ... November 24, 2015 , ... This fall, global ... competitive events in five states to develop and pitch their BIG ideas to improve ... each state are competing for votes to win the title of SAP's Teen Innovator, ...
(Date:11/24/2015)... 24, 2015 SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its ... at 11:00 a.m. Israel time, at the law ... Allon Street, 36 th Floor, Tel Aviv, Israel ... and Izhak Tamir to the Board of Directors; ... directors; , approval of an amendment to certain terms of options ...
(Date:11/24/2015)... Nov. 24, 2015  Twist Bioscience, a company ... Leproust, Ph.D., Twist Bioscience chief executive officer, will ... on December 1, 2015 at 3:10 p.m. Eastern ... City. --> --> ... Twist Bioscience is on Twitter. Sign up to ...
Breaking Biology Technology:
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... --  Growing need for low-cost, easy to use, ... the way for use of biochemical sensors for ... clinical, agricultural, environmental, food and defense applications. Presently, ... applications, however, their adoption is increasing in agricultural, ... on improving product quality and growing need to ...
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
Breaking Biology News(10 mins):